Long-acting PrEP could be available as soon as early-2022
America is on the brink of approving a long-acting HIV prevention medication that is easier to take than daily PrEP. On 23 September, the US Food and Drug Administration (FDA) gave cabotegravir priority review status. This means the drug will undergo a review period of six months as opposed to the usual 10. Cabotegravir, commercially known as Cabenuva, is a long-acting version of pre-exposure prophylaxis (PrEP) and is made by ViiV Healthcare. If approved, the drug would make history by becoming the first of its kind on the market. Unlike…
Read More